Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of miR4512 and CXCL2 in autoimmune diseases

A technology of mir4512 and mir-4512, applied in the field of molecular biology and immunology, can solve the problems of unreported miR4512

Inactive Publication Date: 2021-08-31
昆明医科大学第二附属医院
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] SLE has been reported that TLR4 is closely related to SLE, but there is no report on miR4512 at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miR4512 and CXCL2 in autoimmune diseases
  • Application of miR4512 and CXCL2 in autoimmune diseases
  • Application of miR4512 and CXCL2 in autoimmune diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Such as Figure 1 to Figure 5 As shown, the application of a miR4512 and CXCL2 antibody of the present invention in the preparation of drugs for autoimmune diseases.

[0026] Application of the CXCL2 antibody in the preparation of medicines for improving the symptoms of MRL / lpr in lupus mice.

[0027] The CXCL2 antibody can alleviate kidney damage in lupus mice, including: reduction of 24-hour urine protein, improvement of kidney pathology and reduction of inflammatory cell infiltration, and can regulate ANA, ds-DNA and cell inflammation of MRL / lpr in lupus mice factor secretion.

[0028] The inflammatory cytokines are IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-α, IFN-γ and IL-17; the CXCL2 antibody can reduce The formation of NETs can reduce the aggregation of neutrophils and monocytes in the glomerulus, thereby reducing inflammation; the CXCL2 is a therapeutic target for SLE, LN and other autoimmune diseases.

[0029] In the serum of patients with systemic lupus eryth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of miR4512 and CXCL2 antibodies in preparation of drugs for autoimmune diseases. The CXCL2 antibody is applied to preparation of drugs for improving symptoms of lupus mouse MRL / lpr. The CXCL2 antibody can alleviate kidney damage of lupus mice, including reduction of 24-hour urine protein, improvement of kidney pathology and reduction of inflammatory cell infiltration, and also can regulate and control ANA, ds-DNA and secretion of cell inflammatory factors (IL-1 beta, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-alpha, IFN-gamma and IL-17) of lupus mouse MRL / lpr.

Description

technical field [0001] The invention relates to the technical fields of molecular biology and immunology, in particular to an application of miR4512 and CXCL2 in autoimmune diseases. Background technique [0002] Autoimmune disease (Autoimmune Diseases, AD) refers to the body's immune response to self-antigens, resulting in damage to its own tissues. The exact pathogenesis of autoimmune diseases is unknown, and it is closely related to various immune abnormalities. Autoimmune diseases often have the following common characteristics: ①Patients have obvious familial tendencies, many of which are related to HLA antigens, especially D / DR gene loci, and women are more than men; ②There are high titers of autoantibodies and (or) sensitized lymphocytes that can react with their own tissue components; ③The disease often presents a recurrent and chronic protracted process; ④The etiology is mostly unknown, and a few are caused by drugs (immune hemolytic anemia, thrombocytopenic purpur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7088A61K39/395A61P37/02A61P13/12
CPCA61K31/7088A61K39/3955A61P37/02A61P13/12
Inventor 邓丹琪杨滨宾黄新伟
Owner 昆明医科大学第二附属医院